Wearables, robotics and AI are just three technologies driving the evolution of the medical devices industry. Locations with access to expertise in those and other IT fields will likely have an edge in attracting capital investment in this critical sector. But labor supply in general remains a key location consideration as device manufacturing requires many other skillsets, technical and otherwise.
Analysis from Statista lists in vitro diagnostics, cardiology, diagnostic imaging and orthopedics as the leading segments in the medical technology industry, so project numbers for companies in those areas will likely grow.
Nipro Medical Senior Managing Director of Global Business Tsuyoshi Yamazaki addresses attendees at the company’s project announcement in July.
Photos by Aaron Hines courtesy of City of Greenville
One region seeing increasing investment from medical device manufacturers is eastern North Carolina. Its main metro, Greenville, is 90 minutes east of Raleigh. According to the Greenville Eastern North Carolina Alliance, the area is home to more than 25 medical device and supply companies that combined employ about 700 workers. Greenville is home to East Carolina University and has a medical district anchored by ECU Health Medical Center.
It’s also where Nipro Medical Corporation, a division of Nipro Corporation Japan, is building its first North American manufacturing facility. It will produce devices catering to patients with diabetes, obesity and renal conditions. The company is investing $398 million in the project, which will create 232 new jobs.
“We are thrilled to start manufacturing our cutting-edge medical devices in the U.S., which will support local health care professionals and patients with a stable supply chain and reduced transportation costs,” said Nipro Senior Managing Director of Global Business Tsuyoshi Yamazaki at the July 17th project announcement. “Our close proximity to customers will allow us to better respond to their needs and provide them with timely and effective solutions. Our new facility in Greenville is a major milestone in our sustainability journey, reflecting our commitment to reducing our carbon footprint.”
As part of its announcement Nipro Medical furnished a set of questions and answers that address in more detail the company’s Greenville location selection and its plans for the facility once it’s operational. Following are highlights.
What led to the decision for Nipro to open a new facility in the U.S.?
Nipro’s initiative in North Carolina is focused on delivering top-tier dialysis care as well as supplying pharmaceutical needles to pharmaceutical companies.
“These blossoms are a nod to the company’s Japanese heritage and its commitment to thriving within the local community.”
Why are cherry and dogwood blossoms significant to Nipro’s new facility?
The cherry blossom, emblematic of renewal and optimism, coupled with the dogwood flower (official state flower of North Carolina), emblematic of resilience and fortitude, represent Nipro’s aspirations for growth and strength in the U.S. These blossoms are a nod to the company’s Japanese heritage and its commitment to thriving within the local community.
Is there a plan for Nipro to manufacture in the U.S. and export?
The primary mission of the North Carolina facility is to cater to the North American market’s needs. However, given Nipro’s extensive global network, the possibility of exporting to other regions, such as Latin America, remains open for future consideration.
What impact will the new facility have on the local community and environment?
Nipro’s local manufacturing of dialyzers and precision needles is expected to bolster the local economy through job creation and contribute to environmental sustainability by minimizing the carbon footprint associated with long-distance transport of medical supplies.
What types of products will the North Carolina facility focus on?
The new facility is set to produce state-of-the-art medical devices that support patients with diabetes, chronic kidney disease and other renal health issues, reflecting Nipro’s commitment to enhancing the quality of patient care through innovative medical technologies.
How does Nipro view its role in the health care sector?
Nipro’s dedication to the health care industry is evident in its commitment to meeting the immediate health care needs of the American people. The company’s focus on local production underscores its role as a key player in the global health care landscape.
What workforce will Nipro be looking for?
Nipro values ownership, flexibility and team spirit among its employees. Willingness was the one thing that pushed its founder, and that spirit has carried forward. People who are willing to make a difference and to contribute to our mission are welcome to join us and grow with us.
When will Nipro start to build?
The first products from our new facility are expected to be released following the completion of foundation and construction, which will begin in Q4 2024.
When will the first products be released from this new facility?
The first products from our new facility are scheduled to be released in Q3 2027. We appreciate your interest and will keep you updated as we approach this milestone.
